BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
Key Highlights
- ➤BioCryst forms seven-member Scientific Advisory Board for rare disease R&D strategy
- ➤BioCryst shifts toward external innovation to build a high-value novel drug pipeline
- ➤Scientific Advisory Board will guide pipeline expansion, external opportunities and clinical development
- ➤Board adds expertise spanning rare disease discovery, translational science and regulatory strategy
Expert Statements
Sandeep Menon, Chief Research and Development Officer of BioCryst
“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution of our new R&D model”
Sandeep Menon, Chief Research and Development Officer of BioCryst
“External innovation is increasingly central to how we build our pipeline, and guidance from leading scientists and physicians will sharpen our thinking and strengthen the diligence behind each program we evaluate and advance.”
Sandeep Menon, Chief Research and Development Officer of BioCryst
“The Scientific Advisory Board will work closely with me and our Chief Scientific Officer, Dr. David Jenkins, as we shape and execute BioCryst’s R&D strategy.”
Charlie Gayer, Chief Executive Officer of BioCryst
“Building on our success in developing and commercializing medicines for hereditary angioedema, we are bringing the same rigor to the next generation of BioCryst medicines”
Charlie Gayer, Chief Executive Officer of BioCryst
“With the expertise of these highly experienced scientific advisors, BioCryst will be better positioned to evaluate emerging opportunities and translate their potential into meaningful benefits for patients.”
Anthony Manning, Chair of the Scientific Advisory Board
“Few companies have demonstrated BioCryst’s ability to translate rigorous science into rare disease medicines that reach patients, and that track record is what makes the Company’s evolution so compelling”
Anthony Manning, Chair of the Scientific Advisory Board
“The formation of this Board is an important step for BioCryst, and it is a privilege to chair a group with this depth of experience across rare disease drug discovery, translational science and clinical development.”
Anthony Manning, Chair of the Scientific Advisory Board
“I am confident the Company’s decisions about which science to pursue and how to advance it will benefit from the collective judgment of its members.”
—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—
RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. The SAB will provide independent scientific and strategic guidance as the Company advances its research and development strategy and builds a high value novel drug pipeline.
Get started
Create a free account to read the full story.